Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.51 |
| ▸ | CTSB | P07858 | 5/20 | 0.51 |
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8634476 | 0.85 | CTSL (0.57) | CTSLCTSBCTSKCTSSMEN1 | |
| SCHEMBL17138236 | 0.84 | CTSL (0.47) | CTSLCTSBCTSKCTSSCASP1 | |
| SCHEMBL17138232 | 0.84 | CTSL (0.47) | CTSLCTSBCTSKCTSSCASP1 | |
| SCHEMBL17138254 | 0.78 | L3MBTL1 (0.43) | MEN1LMNAKMT2A | |
| SCHEMBL5689428 | 0.75 | CTSL (0.66) | CTSLCTSBCTSKCTSSCASP1 | |
| SCHEMBL6611310 | 0.72 | TRPM8 (0.56) | CTSLCTSBCTSKCTSSELANE | |
| SCHEMBL15130921 | 0.72 | CTSL (0.72) | CTSLCTSBCTSKCTSSMEN1 | |
| SCHEMBL2580714 | 0.72 | CTSL (0.52) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL3221965 | 0.72 | CTSL (0.52) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL3221956 | 0.72 | CTSL (0.52) | CTSLCTSBCTSKCTSSCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9260478-B2 | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis | HU SHANGHUI (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | NGLY1, VIP, DNPEP | CTSL 446/4885CTSB 322/4885CTSK 460/4885 |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | NGLY1, VIP, DNPEP | CTSL 446/4885CTSB 322/4885CTSK 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.